NextCure NXTC 深 滬
已收盤 12-05 16:00:00 美东时间
12.335
-0.395
-3.10%
華盛通- 最 高12.81
- 今 開12.40
- 成交量 2.50万股
- 最 低 12.10
- 昨 收 12.73
- 總市值 3305.53万
- 52周最高 15.7399
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 2.688
- 委 比 -83.05%
- 總股本 267.98万
- 歷史最高 1308.00
- 量 比 0.58
- 振 幅 5.58%
- 歷史最低 2.688
- 每 手 1
- 風險率 2.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NextCure Files For Offering Of Up To 2.52M Common Shares By Selling Stockholders
- SEC Filing
11-27 05:05
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
NextCure, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. A live audio webcast will be available through the company’s website, with a replay archived for 30 days. NextCure focuses on developing innovative cancer therapies, including antibody-drug conjugates, targeting patients who do not respond to current treatments. The company emphasizes understanding biological pathways and...
11-20 13:00
NextCure Raises $21.5M in Private Placement
NextCure ( ($NXTC) ) has issued an announcement. On November 12, 2025, NextCure...
11-17 21:44
NextCure shares are trading higher after the company announced a $21.5 million private placement.
NextCure shares are trading higher after the company announced a $21.5 million ...
11-12 21:05
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target
Ladenburg Thalmann analyst Kevin DeGeeter upgrades NextCure (NASDAQ:NXTC) from Neutral to Buy and announces $18 price target.
11-07 20:49
NextCure Q3 EPS $(3.22) Beats $(3.98) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(3.22) per share which beat the analyst consensus estimate of $(3.98) by 19.16 percent. This is a 34.95 percent increase over losses of $(4.95) per share from the same
11-06 05:52
先声再明新型ADC候选药物SIM0505完成Ⅰ期临床美国首例患者入组
•首例美国患者已完成给药，已有剂量组已观察到多重应答； • 多区域试验将加速概念验证，预计于2026年上半年获得数据。 中国上海/美国马里兰州贝尔茨...
10-16 21:14
NextCure Doses First U.S. Patient With SIM0505 In Global Phase 1 Cancer Trial; Targets Proof-Of-Concept Data By 1H 2026
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE
10-16 20:09
